A Detailed Analysis of the Cancer Tissue Diagnostics Market Based on Spotlight on Oncology, An Astonishing Rise in Cancer Prevalence, and Technological Advancements
Report ID: PMRREP33842
Number of Pages: 217
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: January-2024
1. Executive Summary
1.1. Global Cancer Tissue Diagnostics Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Test Type Lifecycle Analysis
2.4. Cancer Tissue Diagnostics Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Cancer Tissue Diagnostics Market Outlook: Test Type
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Test Type, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
3.3.3.1. Breast Cancer
3.3.3.2. Stomach (Gastric) Cancer
3.3.3.3. Colorectal Cancer
3.3.3.4. Prostate Cancer
3.3.3.5. Others
3.4. Market Attractiveness Analysis: Test Type
3.5. Global Cancer Tissue Diagnostics Market Outlook: In Situ Hybridization (ISH) Test
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By In Situ Hybridization (ISH) Test, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
3.5.3.1. Breast Cancer
3.5.3.2. Non-Small Cell Lung Cancer (NSCLC)
3.5.3.3. Bladder Cancer
3.5.3.4. Others
3.6. Market Attractiveness Analysis: In Situ Hybridization (ISH) Test
4. Global Cancer Tissue Diagnostics Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Test Type
5.3.3. By In Situ Hybridization (ISH) Test
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
5.5.1. Breast Cancer
5.5.2. Stomach (Gastric) Cancer
5.5.3. Colorectal Cancer
5.5.4. Prostate Cancer
5.5.5. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
5.6.1. Breast Cancer
5.6.2. Non-Small Cell Lung Cancer (NSCLC)
5.6.3. Bladder Cancer
5.6.4. Others
5.7. Market Attractiveness Analysis
6. Europe Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Test Type
6.3.3. By In Situ Hybridization (ISH) Test
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
6.5.1. Breast Cancer
6.5.2. Stomach (Gastric) Cancer
6.5.3. Colorectal Cancer
6.5.4. Prostate Cancer
6.5.5. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
6.6.1. Breast Cancer
6.6.2. Non-Small Cell Lung Cancer (NSCLC)
6.6.3. Bladder Cancer
6.6.4. Others
6.7. Market Attractiveness Analysis
7. East Asia Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Test Type
7.3.3. By In Situ Hybridization (ISH) Test
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
7.5.1. Breast Cancer
7.5.2. Stomach (Gastric) Cancer
7.5.3. Colorectal Cancer
7.5.4. Prostate Cancer
7.5.5. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
7.6.1. Breast Cancer
7.6.2. Non-Small Cell Lung Cancer (NSCLC)
7.6.3. Bladder Cancer
7.6.4. Others
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Test Type
8.3.3. By In Situ Hybridization (ISH) Test
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
8.5.1. Breast Cancer
8.5.2. Stomach (Gastric) Cancer
8.5.3. Colorectal Cancer
8.5.4. Prostate Cancer
8.5.5. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
8.6.1. Breast Cancer
8.6.2. Non-Small Cell Lung Cancer (NSCLC)
8.6.3. Bladder Cancer
8.6.4. Others
8.7. Market Attractiveness Analysis
9. Latin America Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By In Situ Hybridization (ISH) Test
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
9.5.1. Breast Cancer
9.5.2. Stomach (Gastric) Cancer
9.5.3. Colorectal Cancer
9.5.4. Prostate Cancer
9.5.5. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
9.6.1. Breast Cancer
9.6.2. Non-Small Cell Lung Cancer (NSCLC)
9.6.3. Bladder Cancer
9.6.4. Others
9.7. Market Attractiveness Analysis
10. Middle East & Africa Cancer Tissue Diagnostics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By In Situ Hybridization (ISH) Test
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
10.5.1. Breast Cancer
10.5.2. Stomach (Gastric) Cancer
10.5.3. Colorectal Cancer
10.5.4. Prostate Cancer
10.5.5. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By In Situ Hybridization (ISH) Test, 2023 - 2030
10.6.1. Breast Cancer
10.6.2. Non-Small Cell Lung Cancer (NSCLC)
10.6.3. Bladder Cancer
10.6.4. Others
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Abbott Laboratories
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. F. Hoffmann-La Roche Ltd.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Thermo Fisher Scientific Inc.
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Ventana Medical Systems, Inc.
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Bio Rad Laboratories Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Enzo Life Sciences, Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Abcam plc.
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. BioGenex
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Cell Signalling Technology, Inc.
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Agilent Technologies, Inc.
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. PerkinElmer Inc.
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Bio SB
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Cancer Genetics Inc.
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Danaher Corporation
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. ROSETTA GENOMICS
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
11.3.16. Nanoprobes, Inc.
11.3.16.1. Overview
11.3.16.2. Segments and Product
11.3.16.3. Key Financials
11.3.16.4. Market Developments
11.3.16.5. Market Strategy
11.3.17. Creative-Biolabs
11.3.17.1. Overview
11.3.17.2. Segments and Product
11.3.17.3. Key Financials
11.3.17.4. Market Developments
11.3.17.5. Market Strategy
11.3.18. Enzo Life Sciences, Inc.
11.3.18.1. Overview
11.3.18.2. Segments and Product
11.3.18.3. Key Financials
11.3.18.4. Market Developments
11.3.18.5. Market Strategy
11.3.19. Sigma-Aldrich Co., LLC
11.3.19.1. Overview
11.3.19.2. Segments and Product
11.3.19.3. Key Financials
11.3.19.4. Market Developments
11.3.19.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
